Trichostatin A (TSA) 化学構造
分子量: 302.4

高品質保証

カスタマーフィードバック(4)

MSDS

製品説明

  • Compare HDAC Inhibitors
    HDAC製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法
  • Trichostatin A (TSA)のメカニズム

製品の説明

生物活性

製品説明 Trichostatin A (TSA) は、HDAC阻害剤で、IC50 が ~1.8 nM。
ターゲット

HDAC

IC50

~1.8 nM [1]

In vitro試験 Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HEK 293 MkLtSpVv[3Srb36gRZN{[Xl? NFnvZ|gxNjgQvF2= NVfuNWlDOjSq NXHBOIlR\XSqYX7vcC=> NXTzVXNY\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= NWm5VYlEOjV5OEewO|k>
TE13 MoC2SpVv[3Srb36gRZN{[Xl? NGDFPIwxNjQQvF2= M3yxW|I1cA>? NH\yNFR2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> NY\3Z3lqOjV3N{m2OlU>
TE13 MVnBdI9xfG:|aYOgRZN{[Xl? NGXUOIsxNjQQvF2= NVn6T4xiOjSq M1W5eIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MonZNlU2Pzl4NkW=
MEFs M1fJSmZ2dmO2aX;uJGF{e2G7 MlPEOe69VQ>? MV6xOog> MnHubY5kemWjc3XzJJRp\SCHUFXDJIF1fGGlaH3lcpQtKFSrcjDk[YxqfmW{eTDhcoQhfGinIHXm[olkcWWwY4mgc4YheGWmZYP0ZYwh\m:{bXH0bY9v NUnPTFZQOjV2OEK2N|Q>
SW480  M1jrcmZ2dmO2aX;uJGF{e2G7 MXSwMlHPxE1? M1\lb|Q5cA>? NVXodVF1TE2VTx?= MXny[ZZmenOnczDFUXQ> NXSxNlZYOjV2M{S5PVc>
PC3  M3HPNGZ2dmO2aX;uJGF{e2G7 MVWwMlHPxE1? NVPwTI5[PDiq NGP6XHRFVVOR MkDKdoV3\XK|ZYOgSW1V M1rVRlI2PDN2OUm3
SW480  NVG2dZM6TnWwY4Tpc44hSXO|YYm= MlrUNE4y|ryP M4jqVVQ5cA>? NITPN|RFVVOR MknGZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w M1LKeFI2PDN2OUm3
PC3  MVLGeY5kfGmxbjDBd5NigQ>? NEHsRYExNjIQvF2= NWfzfXhpPDiq NV\VOIc5TE2VTx?= Mn;NZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w M{fjdFI2PDN2OUm3
SW480  NFPrZYNHfW6ldHnvckBCe3OjeR?= NYS3c4ZTOC5zzszN MX20PIg> MmT0SG1UVw>? M2TidYlv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? NUjXcItGOjV2M{S5PVc>
PC3  NF31XXJHfW6ldHnvckBCe3OjeR?= M{HTWVAvOc7:TR?= MWq0PIg> MWrEUXNQ MlvJbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? M{G2PFI2PDN2OUm3
A431 NEjFWZFCeG:ydH;zbZMhSXO|YYm= Mmm4Nk8yOC93MD:xNFBvVQ>? M3[yfVQ5cA>? NGTkPXJFVVOR MUnpcohq[mm2czD0bIUh[2WubDDndo94fGh? Mo\qNlU{PzFyNkm=
A431 MVrGeY5kfGmxbjDBd5NigQ>? M2DsPVUxdk1? M2TKW|IwPi9zMj:yOIg> MoLmSG1UVw>? MlrZZYN1cX[jdHXzJJAzOSCjbnSgbY5pcWKrdIOgRXRHOyCneIDy[ZN{cW:w NFTWVYkzPTN5MUC2PS=>
MDA-MB-231 NGm3cJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnFW2gxNTZyMH7N MY[yOIg> MV3EUXNQ NXjIUI5{UUN3MDDv[kAyODCwTR?= NXK4Wno4OjVzOUK3NlE>
MCF7 NELtW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ETVAuPjBybl2= Mnv4NlRp M2nJUGROW09? M1HJVGlEPTBib3[gO|VvVQ>? Ml;iNlUyQTJ5MkG=
SKOV-3 NEL0RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXh[nIyNTFyzszN NHPjWVMzPGh? NF76VXJFVVOR NIi3SJVKSzVyIH;mJFUvPs7:TR?= M2DydVI2OTZ7NEmx
A549 NVfrN3R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrob4MyNTFyzszN MkPDNlRp NUizc25lTE2VTx?= M{O5SGlEPTBib3[gN{4z|ryP MkLRNlUyPjl2OUG=
SKOV-3 NEfmO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfjfm9FOC5zLUJOwG0> NFXOPIQ1QGh? M4jKXmROW09? MYLJR|UxKG:oIECuO:69VQ>? M{\nZVI2OTZ7NEmx
A549 NVL1e5FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHBNE4yNTIQvF2= MnfMOFhp MX7EUXNQ NGD1[JJKSzVyIH;mJFAvOjkQvF2= M3z1V|I2OTZ7NEmx
SKOV-3 NI\mbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nmcFAvODFvMD65{txO MYi3Nog> NUDZc2o6TE2VTx?= NIm1ZWVKSzVyIH;mJFAvOzMQvF2= NF7LWnIzPTF4OUS5NS=>
A549 NF36eFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MViwMlAyNTBwOd88US=> M3H2cVczcA>? MmnUSG1UVw>? MV7JR|UxKG:oIECuNFbPxE1? MYCyOVE3QTR7MR?=
HeLa MXzGeY5kfGmxbjDBd5NigQ>? MVuyOVBvVQ>? NXLneVdnOT[q MVjEUXNQ NYK3VlhscW6lcnXhd4V{KEO\UEHBNUBuWk6DIHX4dJJme3Orb39CpC=> NILyTXEzPTFzNk[4PC=>
CNE2 NG[zRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnVTmoyODBvNkCwcm0> NVPpWXZ2OjRxNEivO|Jp MojhbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYSyOFk3QTlyMR?=
PC3 M2nldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf2Z2k{OTByLUGwNFBvVQ>? M2jVR|I1cA>? MnOyTWM2OCCxZjCzNFBvVQ>? NHPTO4kzPDh3NE[1PC=>
LNCaP NEXm[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz6b3IyODBvMUCwNI5O MnTONlRp MnX0TWM2OCCxZjCzNFBvVQ>? M4rzfVI1QDV2NkW4
HeLa  Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPlUJUz|ryP NXP4PFZNPDiq NHrMbnpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl MXGyOFg1PjF|NR?=
HMEC-1  MXfGeY5kfGmxbjDBd5NigQ>? MnrRN|Axdk1? NFfI[FYzPGh? Mnv4bY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> M1zvUVI1PzFyNkOx
HeLa NHfVXlVHfW6ldHnvckBCe3OjeR?= NFTlOoUydU1? MXmwMlVp NF\LfI9i[m:uaYPo[ZMhfGinIITveIFtKEiGQVOgZYN1cX[rdIm= M2TVcFI1PzB5NEe0
ACP02 M{X1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXPNlUxNzN3MD:1NFBvVQ>? MoXQNlRp NHfhfphl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P MnrlNlQ3Pjh3NEe=
ACP03 M{HyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfTS2ozPTBxM{WwM|UxOG6P M2n0TVI1cA>? MVLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O M1\UZVI1PjZ6NUS3
U87 GBM NFfibW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoG3NVAxNzNyMD:1NFAhdk1? NELkNlE4OiCq MoDnNVAxLSCndHjhco9t NXPSW5E{emWmdXPld{Bu\WGwIHPlcIwhdnWvYnXyJIJ6KDNzLDC1OEwh[W6mIEW4xsAm NXPNeo5oOjR2NkS4OFE>
U87 GBM NVK4cZVbTnWwY4Tpc44hSXO|YYm= NYLXUJJrOTByL{WwNEBPdQ>? MVe0PEBp MVGxNFAmKGW2aHHuc4w> NE\Qd2FKdmS3Y3XzJHNmdmW|Y3XuZ4UuVGmtZTDBcJRmemG2aX;ud{BqdiCQdXPs[YFzKE2xcoDoc4xw\3l? M3L6U|I1PDZ2OESx
RPE NF3oeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjPb|gxNjJxMD60M|AvQC9zIN88US=> MlXvNlQwPDhxN{KgbC=> NGnsVVBFVVOR NV3ncJRHcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? MWqyOFQ2PjZyMh?=
HT29  NX\l[3BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jqb|E5OCCwTR?= MXi3NkBp NVTi[JZWUUN3MDDv[kAyQDBibl2= M13BfVI1OzZ6Mk[1
hMSCs NV\SW4ZsTnWwY4Tpc44hSXO|YYm= MXm2MlI2KG6P NXzObIhUOjRiaB?= MUXEUXNQ NYW1TXhie3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> MlTiNlQ{OTJ|NU[=
Huh7  NEiwXoVHfW6ldHnvckBCe3OjeR?= NXvFVYd2OC5zL{CuOU8yNjBizszN NXq2doY1OjSq MXXzeZBxemW|c3XzJHlVUESFMjDn[Y5mKGW6cILld5Nqd25? NHjRUYkzPDJ4OU[3Ni=>
SKOV3 M3rrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXj[FMxNjB3LUKg{txO MU[xNE8zPC92ODDo NYn4dXR[TE2VTx?= MXnt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M33HflI1OjJ|OECx
A2780 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSwMlA2NTJizszN NYnvOXA2OTBxMkSvOFghcA>? MYLEUXNQ NWTB[2ZSdWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M3TzSVI1OjJ|OECx
SRA01/04  NULNfFBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nZd|AvOiEQvF2= NHPXUIE1QCCq M3nFb2ROW09? NHHXfol{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? MYmyOFE2Pzh5OB?=
HLEB3 NIf2[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jRNlAvOiEQvF2= M3;ISFQ5KGh? NF3CSoVFVVOR NGnTcFN{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? NIr4XHYzPDF3N{i3PC=>
SRA01/04  Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnxWXcxNjRxMD64JO69VQ>? MXS0PEBp M3jRUGROW09? NVL6OWhTcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M1XYZ|I1OTV5OEe4
HLEB3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFeyXnQxNjRxMD64JO69VQ>? NHL3Rms1QCCq M4[3XWROW09? NXf4cFU5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NIfwN2YzPDF3N{i3PC=>
HCT116 NHXQeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fQVVAvOiEQvF2= MX6xNkBp MkHL[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36= NUSwR3hVOjRzMkKyN|E>
CA46 NUDOSW9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDCS492Oy94L{GyM|I1NzR6IH7N MVO0PEBp MUDpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGG2IEK0JIFv\CB2ODDuUeKh NWntWFJGOjRyNkS5OVE>
PMNs MX7GeY5kfGmxbjDBd5NigQ>? NXrXVVQxOzBibl2= MYO0PEBp NWWwN|lwcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6 NWXzbIpyOjN7OEi2NVc>
H1299 M{DFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yxNVHDqM7:TdMg M2rNSVI1NzR6L{eyJIg> M3z2R4V1cGGwb3y= M33Zeolv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? MY[yN|kyPjZyOR?=
A549 M1PycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDmR5N5OC5{NT:wMlUwOSEQvF2= M1K4XlI1NzR6L{eyJIg> MlrE[ZRp[W6xbB?= NH;2bpBqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NYPISIlMOjN6Nke5PVE>
H1299 NUTCcGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOwMlI2NzBwNT:xJO69VQ>? MkHvNlQwPDhxN{KgbC=> NXnGTG5D\XSqYX7vcC=> MUPpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz M3nWRVI{QDZ5OUmx
A549 NU\vRnN4SXCxcITvd4l{KEG|c3H5 NGH6S5ExNjVxMTFOwG0> M1\QN|Q5KGh? MVzleIhidm:u MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MnjGNlM5Pjd7OUG=
H1299 NEjrXYpCeG:ydH;zbZMhSXO|YYm= NGr5[o8xNjVxMTFOwG0> NFvIXFg1QCCq MY\leIhidm:u NULhXlJ4cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NXX0SndTOjN6Nke5PVE>
SUM149PT MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofiNk84NjVxMUCg{txO M2fSNVQ5KGh? MlLVSG1UVw>? NHLLO3RqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= M3;kVFI{Pzl{NkO4
SUM190PT MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfUd5M{PTBxMUCwM|I2OCCwTR?= NEft[HU1QCCq NUjRXFhwTE2VTx?= NX;Me29bcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEWwJI5OKHOnboPpeIl3\Wy7 NHz0[pozOzd7Mk[zPC=>
HCT1 NIe2SYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXueIoxNjJxMT6wM|UvOCEQvF2= MYCxNk8zPC9|Nj:0PEBp NILrbY1qdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MWmyN|c4ODByMB?=
Lovo MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fyeFAvOi9zLkCvOU4xKM7:TR?= M{\hTVEzNzJ2L{O2M|Q5KGh? NFvsdlZqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> Mnj6NlM4PzByMEC=
AGS M4L6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rCblAvODF3LUGg{txO MlrHO|IhcA>? NHXmNFJqdmS3Y3XzJINmdGxiZHXheIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> NVzFRWd2OjN5NEWwNlQ>
Huh7 M3jDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\FdFEh|ryP MmewNlQhcA>? NHTmU2lFVVOR NITaSItz\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>? MorNNlM3PDN7M{O=
ECC1 MWHGeY5kfGmxbjDBd5NigQ>? NICwXXQ2ODBibl2= NF7Lc5Q2KGR? M3n4NGROW09? MVLpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MViyN|U{ODd4OR?=
HEC1A NHrScotHfW6ldHnvckBCe3OjeR?= MkDQOVAxKG6P M3jkc|Uh\A>? NGewVnFFVVOR MmjKbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? MoTQNlM2OzB5Nkm=
EN1 NYTJbmZbTnWwY4Tpc44hSXO|YYm= NXzLOo9yPTByIH7N NFXoc5A2KGR? MXfEUXNQ M4r4Solv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MXmyN|U{ODd4OR?=
MFE296 MmPySpVv[3Srb36gRZN{[Xl? MUe1NFAhdk1? M3jHbVUh\A>? MmLVSG1UVw>? M3e2Oolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF M4\o[|I{PTNyN{[5
HASMCs MXHGeY5kfGmxbjDBd5NigQ>? NEH5UXAxNTVyMDDuUS=> NXmxepl7PiCm Mn3L[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk> Ml;jNlM2OTh2Nke=
U373 M4PaOWZ2dmO2aX;uJGF{e2G7 M2fDSVAvOjVxMD61M|Eh|ryP MV2yOEBp MnewbY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN? MlPPNlM1PzRzN{G=
ARN8  MUXGeY5kfGmxbjDBd5NigQ>? NF3LVXgxNjB3LUKg{txO NUmwc29jOjRiaB?= MYXy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> NIfXTXQzOzR5MEW0NC=>
MCF7 NIewdVdHfW6ldHnvckBCe3OjeR?= MV2wMlA2NTJizszN M3;HOVI1KGh? MULy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> MVuyN|Q4ODV2MB?=
H1299  NVrOdpI3TnWwY4Tpc44hSXO|YYm= MUiwMlM{6oDVMdMgxtVO Mmm1NlQwPDhiaB?= MULEUXNQ MXvpcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 M2XkblI{PDZzOUe1
H1299 NVzNUWpmTnWwY4Tpc44hSXO|YYm= MU[wMlUh|ryP M1L0U|Q5KGh? NX\1T|Z7TE2VTx?= M2HqSolvcGmkaYTzJJRp\SCvaXfyZZRwenlicH;0[Y51cWGuIHPvcYJqdmVid3n0bEB{cWyrYnnubY4> MoTFNlM1PjF7N{W=
H1299 NFzhdmVHfW6ldHnvckBCe3OjeR?= NIHuUW0xNjVizszN NXLKUJVHPDhiaB?= MYfEUXNQ MV7pcohq[mm2czD0bIUhcW64YYPpeoVv\XO|wrCgZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MYKyN|Q3OTl5NR?=
MG-63  NWrr[|Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInrblQxNjNizszN NW[xS5l3OTJvOU[gbC=> NH;GWIFFVVOR MYnpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw MXmyN|Q2OThzNx?=
LM8 NV7J[2JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLGSFN4OC5|IN88US=> NIrQTnEyOi17NjDo MYLEUXNQ MmTGbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= NF;SToUzOzR3MUixOy=>
K562 M1\KdmZ2dmO2aX;uJGF{e2G7 NIruWm0xNjVizszN NF;xS3EzPCCq NWTQRpJN\XSqYX7vcC=> NHzh[pll\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NEmwbGIzOzR|MEm1Oy=>
HEL NEDSXo1HfW6ldHnvckBCe3OjeR?= NF;PS2cxNjVizszN NWiwUYZrOjRiaB?= MnjN[ZRp[W6xbB?= MX\k[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> M1LzW|I{PDNyOUW3
HL60 M3HBcmFxd3C2b4Ppd{BCe3OjeR?= M4DVdlEh|ryP NVnvOnRKOjRiaB?= MmCybY5lfWOnc9MgZ4VtdCCmZXH0bC=> MoDSNlM1ODB3MUm=
KG1 MnvZRZBweHSxc3nzJGF{e2G7 MoGyNUDPxE1? MXmyOEBp NX63fHhkcW6mdXPld:Kh[2WubDDk[YF1cA>? NX34SoF7OjN2MEC1NVk>
Kazumi MWLBdI9xfG:|aYOgRZN{[Xl? MWixJO69VQ>? M37RdFI1KGh? MmjibY5lfWOnc9MgZ4VtdCCmZXH0bC=> NVzCO4o1OjN2MEC1NVk>
K562 NELLfYpCeG:ydH;zbZMhSXO|YYm= Mnn4NUDPxE1? MYiyOEBp NW\2TnRJcW6mdXPld:Kh[2WubDDk[YF1cA>? MmDuNlM1ODB3MUm=
THP1 NH70VY9CeG:ydH;zbZMhSXO|YYm= NUnzRmlZOSEQvF2= NVPJTmI6OjRiaB?= M2rkZolv\HWlZYRCpINmdGxiZHXheIg> M4i4WVI{PDByNUG5
SH-SY5Y MnOxSpVv[3Srb36gRZN{[Xl? MlHyNlUxKG6P NGLlRWoyPiCq MnT4Z4hidmenczDlfJBz\XO|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m|LDD1dJRic2ViYX7kJIVn\my3eB?= NWnyOWlzOjN|Mk[0NlI>
HEK293 NYPEWoZ[TnWwY4Tpc44hSXO|YYm= MnXVNUDDvU4EoB?= MWKxPEBpyqB? M{XKbolvcGmkaYTzJJRp\SCtYXzpdolvNTdvbXXkbYF1\WRicnXjdpVqfG2nboSgc4Yhe3mwcHjpcIlvNTFiYXfndoVo[XSnczDpcpRwKGGpZ4Lld49u\XN? NG\idIszOzJ6NEi0PC=>
HTK MUTGeY5kfGmxbjDBd5NigQ>? MkGwOFAxKG6P NYPUTlQ{PzJiaB?= MnnSbY5pcWKrdIOgWGdHNc7{4pETTY5lfWOnZDDNfY9ncWK{b3LsZZN1KESrZn\ldoVvfGmjdHnvci=> MV6yN|I5PDByMh?=
HTK MYTGeY5kfGmxbjDBd5NigQ>? NITkdpUyODBvOECwcm0> M2\4VlczKGh? NV;IWohP[myxY3vzJHRITi4QsvMAl2lv\HWlZXSgVm9UKGGwZDDINm8zyqCDY3P1cZVt[XSrb36= NHT0eogzOzJ6NECwNi=>
Caco-2  NIfscnJHfW6ldHnvckBCe3OjeR?= MWqxJOK2VcLi NX3yXW1kOjRiaB?= MVvk[YNz\WG|ZYOgV2VTXCCycn;0[YlvKGW6cILld5Nqd25? MoDqNlMyQTVyN{C=
HeLa NIraenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDIVYJtOTByIH7N MYOyOEBp NGXneGpFVVOR M1;BVmlEPTBib3[gNVAxdk1? NX7ud4E2OjNzNkW3OFg>
HeLa MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjBOFAhdk1? MVy0PEBp M3XXSmROW09? MWnJR|UxKG:oIESwcm0> MmrVNlMyPjV5NEi=
HeLa MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPINlAhdk1? MYm3NkBp M3r5R2ROW09? MW\JR|UxKG:oIEKwcm0> NFntUIYzOzF4NUe0PC=>
HeLa M13oTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonFNVAwOzBxNUCgcm0> M3XkOVczKGh? Mnm2SG1UVw>? Ml\zbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5 MlTxNlMyPjV5NEi=
MDA-MB-231 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTCNlUuPDByIH7N MYq0PEBp NGr0fJRKSzVyIH;mJFI3Oy5{bl5CpC=> M1nVRVI{ODV3MUm4
MCF-7  NGr0Z2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCyOU01ODBibl2= NH3SfVc1QCCq NEXCT5BKSzVyIH;mJFIzOC52bl2= NFjBc3ozOzB3NUG5PC=>
ECC-1  NFXWfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXKcIgyODBibl2= NGHBXlQzPCCq M{TVPIV1cGGwb3y= NILGNmpqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|NTW= MorINlMxOjh6MEO=
HEC-1A MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[5XlExOCCwTR?= NG\Sc3IzPCCq MnPN[ZRp[W6xbB?= MoPhbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzln MmD2NlMxOjh6MEO=
NHAC-kn MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33YblExNzFyMD:1NFAhdk1? MYCxNkBp NXS3OFJiTE2VTx?= MmrtTWM2OCCxZjC1NFBvVQ>? M3XHWFI{ODF5OEex
A549 NHzrUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS0S20zPTBibl2= NW\KVJd7Pi15MjDo NFzoNlZFVVOR NFq5N4Rk[XW|ZYOgZUBoemWjdHXyJIlvcGmkaYTvdpkh\W[oZXP0JINwdWKrbnWge4l1cCCWWGSgc5Ih\XKub4Tpcolj NUXVR3pnOjJ7OUS3PFA>
MG-63 NWfLPJZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjaUpg{ODBibl2= M320TVEzKGh? MVLEUXNQ NH7IbmNqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn MXGyNlc6QTN|OB?=
MG-63 MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPnR|I{ODBibl2= MlnxNlQhcA>? NGq4RWJFVVOR M4LNNIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? NHnFWYUzOjd7OUOzPC=>
MG-63 MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy5NpE{ODBibl2= MnnFOFghcA>? NFHr[WxFVVOR NYn4U41jcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?= MX2yNlc6QTN|OB?=
HL60  NF3hdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\BNVUxNTN3MDDuUS=> M1HrdlI1KGh? MnKxbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> NV7wb5pQOjJ5NUO3N|k>
U937 M1LmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG3XXIyPTBvM{WwJI5O MVmyOEBp M3XHb4lv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> MojJNlI4PTN5M{m=
SCC-6 M{XMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XOOlIxOC1|MkCwJI5O MXGxNk8zPC92ODDo NGD2c4pFVVOR M37scYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKFOFQz22JINmdGy|IHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NYPYPXVkOjJ3NUKzNlE>
U87  NHPFOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrab2UyODBvM{CwJI5o NHv3PG4zPCCq NUfvd3FJcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne= NUXGcZF6OjJ{N{C4OFk>
K562 NIfEZWNHfW6ldHnvckBCe3OjeR?= MVKxJO69VQ>? NInHTWMyOiCq MXTEUXNQ M1u2NIVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS Mn7nNlIyPzlzOUi=
Reh Mo[zSpVv[3Srb36gRZN{[Xl? MoPnNE4{NzFizszN M1PjdFEzKGh? Ml\lSG1UVw>? NH3GN4pmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> Mme0NlIyPzlzOUi=

... Click to View More Cell Line Experimental Data

In vivo試験 Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]
臨床試験
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

In vitro HDAC activity Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.

細胞アッセイ:

[1]

細胞株 MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
濃度 Dissolved in absolute ethanol, final concentrations ~10 μM
反応時間 96 hours
実験の流れ

Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.

動物実験:

[1]

動物モデル Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
製剤 Dissolved in DMSO
投薬量 ~5 mg/kg/day
投与方法 Injection s.c.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Trichostatin A (TSA) SDF
分子量 302.4
化学式

C17H22N2O3

CAS No. 58880-19-6
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 23 mg/mL (76.05 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (R,2E,4E)-6-(4-(dimethylamino)benzoyl)-N-hydroxy-4-methylhepta-2,4-dienamide

文献中の引用 (20)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related HDAC 阻害剤

  • LMK-235

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • 4SC-202

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • HPOB

    HPOB is a potent, selective HDAC6 inhibitor with IC50 of 56 nM, >30-fold selectivity over other HDACs.

  • Panobinostat (LBH589)

    Panobinostat (LBH589)は、MOLT-4とReh細胞のための新しい幅広いスペクトルHDAC阻害剤で、IC50 がそれぞれ 5 と 20 nMになる。Phase 4

  • Vorinostat (SAHA, MK0683)

    Vorinostat (SAHA, MK0683)ボリノスタット(SAHA)は、86nM未満のIC50による強力なクラスIおよびIIヒストン脱アセチル化酵素(HDAC)阻害剤です。

  • Entinostat (MS-275)

    Entinostat (MS-275)は、HDAC1とHDAC3のHDAC阻害剤で、IC50 がそれぞれ 0.51 μM と 1.7 μMです。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)は、強力なヒストン脱アセチル化酵素1と2つの(HDAC1とHDAC2)阻害剤で、 IC50 がそれぞれ 36 nM と 47 nMです。

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966 is a HDAC inhibitor, with an IC50 of 0.08μM for HDAC3, exhibits > 200-fold selectivity over other HDAC.

最近チェックしたアイテム

Tags: Trichostatin A (TSA)を買う | Trichostatin A (TSA)供給者 | Trichostatin A (TSA)を購入する | Trichostatin A (TSA)費用 | Trichostatin A (TSA)生産者 | オーダーTrichostatin A (TSA) | Trichostatin A (TSA)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ